Johnson & Johnson (NYSE:JNJ) Stock Price Down 1.4% – Should You Sell?

Johnson & Johnson (NYSE:JNJ)’s share price was down 1.4% on Wednesday . The stock traded as low as $263.13 and last traded at $263.5160. 6,693,754 shares changed hands during mid-day trading, a decline of 21% from the average session volume of 8,463,563 shares. The stock had previously closed at $267.24.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Bank of America raised its price target on Johnson & Johnson to $263 from $254 while keeping a neutral rating, signaling improved valuation expectations and modest upside from current levels.
• Positive Sentiment: Johnson & Johnson backed the RELIEVE-HFrEF clinical trial for the V-Wave Ventura heart failure device, keeping attention on its cardiovascular innovation pipeline and potential long-term growth opportunities. Article Title
• Positive Sentiment: Recent commentary from analysts and media outlets has highlighted Johnson & Johnson as a strong dividend and defensive healthcare name, which may be supporting investor demand amid sector rotation. Article Title
• Neutral Sentiment: Several preview and comparison pieces ahead of earnings are keeping JNJ in focus, with investors looking for confirmation that the company can continue beating estimates and sustaining growth.
• Neutral Sentiment: Recent articles also noted JNJ’s prior share-price weakness in the context of broader market moves, but that appears more like short-term trading noise than a company-specific concern.
• Negative Sentiment: No major negative company-specific catalyst was reported in the latest batch of articles, though some recent pullbacks suggest investors are still watching for confirmation from upcoming results and trial updates.

Analyst Ratings Changes

Several equities analysts recently issued reports on JNJ shares. Johnson Rice set a $270.00 price objective on Johnson & Johnson in a research note on Friday, June 26th. Citigroup raised their price target on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research report on Wednesday. The Goldman Sachs Group boosted their price objective on shares of Johnson & Johnson from $265.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, April 15th. Bank of America raised their target price on shares of Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a report on Friday. Finally, Guggenheim upped their target price on Johnson & Johnson from $266.00 to $270.00 and gave the company a “buy” rating in a report on Friday, June 26th. Twenty research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $258.13.

Johnson & Johnson Stock Performance

The firm has a market cap of $619.07 billion, a price-to-earnings ratio of 29.73, a PEG ratio of 2.58 and a beta of 0.24. The stock’s fifty day moving average is $236.47 and its two-hundred day moving average is $232.88. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. The firm had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. Johnson & Johnson’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, analysts expect that Johnson & Johnson will post 11.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, May 26th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.97%.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

A number of institutional investors and hedge funds have recently bought and sold shares of JNJ. Tema ETFs LLC raised its holdings in Johnson & Johnson by 4.4% during the second quarter. Tema ETFs LLC now owns 73,885 shares of the company’s stock worth $18,765,000 after purchasing an additional 3,134 shares in the last quarter. Dagco Inc. increased its position in shares of Johnson & Johnson by 21.7% during the 2nd quarter. Dagco Inc. now owns 6,980 shares of the company’s stock valued at $1,773,000 after purchasing an additional 1,243 shares during the period. Rise Advisors LLC increased its position in shares of Johnson & Johnson by 2.8% during the 2nd quarter. Rise Advisors LLC now owns 4,542 shares of the company’s stock valued at $1,154,000 after purchasing an additional 125 shares during the period. Nolet Wealth Management LLC raised its stake in shares of Johnson & Johnson by 6.9% in the 2nd quarter. Nolet Wealth Management LLC now owns 2,581 shares of the company’s stock worth $655,000 after buying an additional 166 shares in the last quarter. Finally, William Mack & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $373,000. Institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.